Skip to main content
Figure 1 | Molecular Medicine

Figure 1

From: BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma

Figure 1

Real-time PCR quantification of BCL2L12 gene expression in NPC tissue biopsies. (A) Amplification plot of BCL2L12 and GAPDH cDNAs, showing ΔRn plotted against the cycle number. BCL2L12 mRNA expression was detected by real-time quantitative PCR using SYBR® Green chemistry, with GAPDH as a reference gene. Calculations were made using the comparative CT (2−ΔΔCT) method. (B) Dissociation curves of the BCL2L12 amplicon, demonstrating the specificity of primers used for the real-time PCR amplification and quantification of BCL2L12. Neither primer-dimers nor other nonspecific products were observed after melting of the PCR products. (C) Validation of the comparative CT (2−ΔΔCT) method to assess the efficiency of amplification of the target gene (BCL2L12) and the internal control (GAPDH). Using reverse transcriptase, cDNA was synthesized from 2 µg total RNA isolated from human HL-60 cells. Serial dilutions of cDNA over a 106-fold range were amplified by real-time PCR using gene-specific primers. The most concentrated sample contained cDNA derived from 100 ng total RNA. BCL2L12 and GAPDH average CT values were calculated for each cDNA dilution and plotted against log cDNA dilution. All data were fit using least-squares linear regression analysis. The absolute values of the slopes of resulting plots are approximately equal, thus implying similar amplification efficiencies for both genes.

Back to article page